Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications = Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications

다국어 초록 (Multilingual Abstract)

Glioblastoma, the most common primary malignant brain tumor in adults, is highly aggressive and associated with a poor prognosis. Bevacizumab, a monoclonal antibody against the vascular endothelial growth factor receptor, has increasingly been used in the treatment of recurrent glioblastoma. It has achieved excellent rates of radiographic response, but most patients will progress after only a few months. Upon recurrence, tumors may not enhance, secondary to vascular normalization. We describe four patterns of radiographic progression commonly associated with Bevacizumab failure: 1) Distant enhancing tumor, 2) Local tumor progression without enhancement, 3) Diffuse gliomatosis-like infiltration, and 4) Local or multifocal progression, with enhancement. Some have noted an increased incidence of distant or diffuse disease upon recurrence, suggestive of a transition to a more aggressive phenotype, but a review of the literature suggests there is no conclusive evidence that Bevacizumab treatment is associated with an increased rate of distant or diffuse recurrence.

참고문헌 (Reference)

1 Ellis LM, "VEGF-targeted therapy: mechanisms of anti-tumour activity" 8 : 579-591, 2008

2 Lu KV, "VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex" 22 : 21-35, 2012

3 Wen PY, "Updated response assessment criteria for high-grade gliomas: response assessment in neurooncology working group" 28 : 1963-1972, 2010

4 de Groot JF, "Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice" 12 : 233-242, 2010

5 Thompson EM, "Treatment with bevacizumab plus carboplatin for recurrent malignant glioma" 67 : 87-93, 2010

6 Bokstein F, "Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors" 112 : 2267-2273, 2008

7 Thompson EM, "The paradoxical effect of bevacizumab in the therapy of malignant gliomas" 76 : 87-93, 2011

8 Taal W, "Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial" 15 : 943-953, 2014

9 Macdonald DR, "Response criteria for phase II studies of supratentorial malignant glioma" 8 : 1277-1280, 1990

10 Prados M, "Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab" 13 : 143-151, 2011

11 Stupp R, "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma" 352 : 987-996, 2005

12 Nowosielski M, "Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma" 82 : 1684-1692, 2014

13 Kreisl TN, "Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma" 27 : 740-745, 2009

14 Vredenburgh JJ, "Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma" 13 : 1253-1259, 2007

15 Pope WB, "Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab" 76 : 432-437, 2011

16 Shapiro LQ, "Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma" 85 : 636-642, 2013

17 Bergers G, "Modes of resistance to anti-angiogenic therapy" 8 : 592-603, 2008

18 Kargiotis O, "Mechanisms of angiogenesis in gliomas" 78 : 281-293, 2006

19 Claes A, "Magnetic resonance imagingbased detection of glial brain tumors in mice after antiangiogenic treatment" 122 : 1981-1986, 2008

20 Pope WB, "MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy" 66 : 1258-1260, 2006

21 Kang TY, "Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety" 89 : 113-118, 2008

22 Kunkel P, "Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2" 61 : 6624-6628, 2001

23 Schwartzbaum JA, "Epidemiology and molecular pathology of glioma" 2 : 494-503, 2006

24 Zuniga RM, "Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan" 91 : 329-336, 2009

25 Wick W, "EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma" 34 : 2016

26 Gilbert MR, "Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial" 31 : 4085-4091, 2013

27 Ostrom QT, "CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011" 16 (16): iv1-iv63, 2014

28 Vredenburgh JJ, "Bevacizumab plus irinotecan in recurrent glioblastoma multiforme" 25 : 4722-4729, 2007

29 Norden AD, "Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence" 70 : 779-787, 2008

30 Ali SA, "Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases" 109 : 268-272, 2008

31 Friedman HS, "Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma" 27 : 4733-4740, 2009

32 Narayana A, "Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival" 110 : 173-180, 2009

33 Rubenstein JL, "Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption" 2 : 306-314, 2000

34 Brandes AA, "AT-11. Final results from the randomized phase II trial avareg (ML25739) with bevacizumab (BEV) or fotemustine (FTM) in recurrent GBM" 16 (16): v10-, 2014